GSK2983559
Based on 2 publication(s) in Google Scholar
GSK2983559 is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 blocks many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples.
For research use only. We do not sell to patients.
- Purity: 99.49%
- Formula: C21H23N4O7PS2.1/2Ca.3H2O
- Molecular Weight:612.63
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) GSK2983559
More
Biological Activity
|
RIPK2 |
GSK2983559 (1-1024 nM; 2 h) blocks MDP-induced IL-8 in THP-1 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:THP-1 cells
-
Concentration:1-1024 nM
-
Incubation Time:2 hours
-
Result:Inhibited IL-8 production with an IC50 of 1.34 nM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (female) injected with MDP (100 μg)[2]
-
Dosage:3 and 10 mg/kg
-
Administration:Oral gavage; 3 and 10 mg/kg; once
-
Result:Suppressed serum IL-6 levels in a dose-dependent manner.
Chemical Information
-
Appearance Solid
-
Molecular Weight 612.63
-
Formula C21H23N4O7PS2.1/2Ca.3H2O
-
Color Yellow to brown
-
SMILES
CC(C)(C)S(C(C(OCCOP(O)([O-])=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O.[H]O[H].[H]O[H].[H]O[H].[Ca+2]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
Solvent & Solubility
DMSO : < 1 mg/mL (insoluble or slightly soluble)
DMF : < 1 mg/mL (insoluble)
Ethanol : < 1 mg/mL (insoluble)
* GSK2983559 is usually formulated as a suspension.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Pamela A Haile, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 Jul 25;62(14):6482-6494. [Content Brief]
[2]. Shuwei Wu, et al. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors. Bioorg Med Chem Lett. 2022 Sep 2;75:128968. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz